Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

TYTa-Chuan YuTHTai‐Chung HuangCLChien‐Chin Lin

Discussion

Loading...

Member takes

Overview

Phase 2 trial demonstrates eltrombopag enhances PBSC harvest in lymphoma patients, indicating improved outcomes.

Key Points

  • This study aims to assess the impact of eltrombopag on autologous PBSC harvest success rates in lymphoma patients.
  • Phase 2, single-arm trial involving East-Asian lymphoma patients
  • Patients received eltrombopag 75 mg daily during ESHAP chemo-mobilization for PBSC harvest
  • Primary endpoint was the proportion of patients obtaining >2.0 × 106/kg CD34+ cells on first apheresis day
  • 29 of 39 patients met the primary endpoint for PBSC harvest
  • Mean CD34+ cell quantity was significantly higher with eltrombopag (13.30 × 106/kg) compared to historical control (5.71 × 106/kg)
  • 12-month progression-free survival was 58.23% after auto-HSCT

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba3https://doi.org/10.1182/blood-2025-5965
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12SPD-005 Alternative to the treatment of poor graft function after haematopoietic stem cell transplantation: eltrombopag2024
  2. 2Comparative study of hetrombopag vs. eltrombopag in promoting platelet engraftment post-autologous hematopoietic stem cell transplantation: A multicenter clinical trial2025
  3. 3A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation2013 · 31 citations
  4. 4Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients2024 · 3 citations
  5. 5<scp>Eltrombopag</scp> Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority <scp>EBMT</scp> ‐ <scp>SAAWP RACE</scp> Study2026